Determination Of Predictive Factors Allowing To An Additional 10% Reduction Of Intra-Ocular Pressure

Back to Search
Print
Bookmark Trial

NCT00230763

Last updated date
Back to Search
Print
Bookmark Trial
FOR MORE INFORMATION
Study Location
Pfizer Investigational Site
Agen, , 47000, France
See other locations
Contact
1-800-718-1021
[email protected]
Related Links

FOR MORE INFORMATION

Contact a representative by phone, email, or visiting the study website. Please see the references below:

By phone

Pfizer Clinical Trials Contact Center

1-800-718-1021

By email

Contact

[email protected]

Call Now

Eligibility Criteria
condition
The disease, disorder, syndrome, illness, or injury that is being studied.
Primary Open Angle (POAG) Glaucoma, Ocular Hypertension
Sex
Females and Males
Age
Pediatric Trials: 0-17 Years
Adult Trials: 18+ Years
18 + years
Inclusion Criteria
The factors, or reasons, that allow a person to participate in a clinical study.
Show details

- Male or female patients,

- Aged > than equal to 18 years,

- Patient presenting with an OHT or OAG with an IOP � 21 mmHg,

- Patient currently treated with ophthalmic beta-blockers monotherapy and requiring a change of the ophthalmic medication due to insufficient response to treatment,

Exclusion Criteria
The factors, or reasons, that prevent a person from participating in a clinical study.
Show details


- Patient currently treated by or having received within the last month any ophthalmic
hypotensive agent other than a beta-blocker,


- Patient presenting any contraindication to latanoprost or timolol,


- Patient with history of asthma, obstructive broncho-pneumopathy, sinusal bradycardia
(pulse rate < 60 bpm), auriculo-ventricular block, cardiac insufficiency, Raynaud
disease or any other condition that would preclude the patient from taking the
prescribed medication,


- Patient with known intolerance to benzalkonium chloride or any excipient contained in
the trial treatment,

NEED INFO?

Questions about a trial? Call or email to reach a Pfizer Clinical Trial Contact Center Representative

Pfizer Clinical Trials Contact Center

1-800-718-1021

[email protected]

Call Now
pfizer-logoClinical Trials
Interested in learning more about clinical trials?
Discover how clinical trials work and the impact your participation could have.
Learn more ›

TRY A NEW SEARCH

Search for Clinical Trials by condition, keyword or trial number. Share your location or enter your city or zip code to find studies near you.

Advanced Search

Based on your search, you may also be interested in

Primary Open Angle (POAG) Glaucoma, Ocular HypertensionDetermination Of Predictive Factors Allowing To An Additional 10% Reduction Of Intra-Ocular Pressure
NCT00230763
  1. Agen,
  2. Amboise,
  3. Amiens,
  4. Andresy,
  5. Asnieres Sur Seine,
  6. Aubiere,
  7. Aurillac,
  8. Belfort,
  9. Besancon,
  10. Beziers,
  11. Bordeaux,
  12. Bourg en Bresse,
  13. Caen,
  14. Cannes,
  15. Castelsarrasin,
  16. Chalon Sur Saone,
  17. Chalons en Champagne,
  18. Chamalieres-Royat,
  19. Chambery,
  20. Chartres,
  21. Chassieu,
  22. Chateau Renault,
  23. Chateaudun,
  24. Clamart,
  25. Clermont Ferrand,
  26. Clermont-Ferrand,
  27. Colmar,
  28. Coulommiers,
  29. Dax,
  30. Etampes,
  31. Figeac,
  32. Frejus,
  33. Goussainville,
  34. Haguenau,
  35. Hyeres,
  36. Issy Les Moulineaux,
  37. Ivry Sur Seine,
  38. Jarny,
  39. La Fleche,
  40. Langon,
  41. Lannion,
  42. Le Mans,
  43. Le Quesnoy,
  44. Les Clayes Sous Bois,
  45. Les Lilas,
  46. Lille,
  47. Limoges,
  48. Luxeuil Les Bains,
  49. Lyon,
  50. Lyon,
  51. Lyon,
  52. Marseille,
  53. Marseille,
  54. Marseille,
  55. Marseille,
  56. Meaux,
  57. Meudon,
  58. Meyzieu,
  59. Montargis,
  60. Montbeliard,
  61. Montigny Le Bretonneux,
  62. Moulins,
  63. Mulhouse,
  64. Nantes,
  65. Nemours,
  66. Nice,
  67. Noeux Les Mines,
  68. Orleans,
  69. Orsay,
  70. Pantin,
  71. Paris,
  72. Paris,
  73. Paris,
  74. Paris,
  75. Pau,
  76. Perpignan,
  77. Poissy,
  78. Quetigny,
  79. Rillieux La Pape,
  80. Roanne,
  81. Roquebrune-Cap-Martin,
  82. Roye,
  83. Saint Laurent Du Var,
  84. Saint Quentin,
  85. Sainte-Maure-de-Touraine,
  86. Saintes,
  87. Salon De Provence,
  88. Sceaux,
  89. St. Girons,
  90. St. Maur Des Fosses,
  91. Toulon,
  92. Toulouse,
  93. Tremblay en France,
  94. Troyes,
  95. Vauvert,
  96. Vendome,
  97. Versailles,
  98. Viarmes,
  99. Villeneuve la Garenne,
  100. Villeparisis,
  101. Villiers Le Bel,
  102. Wasselonne,
ALL GENDERS
18 Years+
years
MULTIPLE SITES
Primary Open Angle (POAG) Glaucoma, Ocular HypertensionA Study Comparing Xalacom And Xalatan In Patients With Primary Open Angle Glaucoma (POAG) Or Ocular Hypertension (OH).
NCT00383019
  1. Ichinomiya, Aichi
  2. Ichinomiya, Aichi
  3. Nagoya, Aichi
  4. Nagoya, Aichi
  5. Nagoya, Aichi
  6. Narashino, Chiba
  7. Sapporo, Hokkaido
  8. Sapporo, Hokkaido
  9. Sapporo, Hokkaido
  10. Sapporo, Hokkaido
  11. Koube, Hyogo
  12. Kanazawa, Ishikawa
  13. Fujisawa, Kanagawa
  14. Kamakura, Kanagawa
  15. Sagamihara, Kanagawa
  16. Yokohama, Kanagawa
  17. Sapporo, Kokkaido
  18. Uji, Kyoto
  19. Miyakonojo, Miyazaki
  20. Kumagaya, Saitama
  21. Tokorozawa, Saitama
  22. Fuji, Shizuoka
  23. Fuji, Shizuoka
  24. Mishima, Shizuoka
  25. Susono, Shizuoka
  26. Bunkyo-ku, Tokyo
  27. Chiyoda-ku, Tokyo
  28. Chiyoda, Tokyo
  29. Hachioji, Tokyo
  30. Hamura, Tokyo
  31. Katsushika-ku, Tokyo
  32. Kiyose, Tokyo
  33. Koto-ku, Tokyo
  34. Meguro-ku, Tokyo
  35. Meguro, Tokyo
  36. Musashino, Tokyo
  37. Musashino, Tokyo
  38. Ota-ku, Tokyo
  39. Setagaya, Tokyo
  40. Shinjuku, Tokyo
  41. Tachikawa, Tokyo
  42. Taito-ku, Tokyo
  43. Fujuoka,
  44. Fukuoka,
  45. Fukuoka,
  46. Fukuoka,
  47. Gifu,
  48. Hiroshima,
  49. Niigata,
  50. Osaka,
  51. Osaka,
  52. Osaka,
  53. Shizuoka,
  54. Sugita,
ALL GENDERS
20 Years+
years
MULTIPLE SITES
Advanced Information
Descriptive Information
Brief Title  ICMJE Determination Of Predictive Factors Allowing To An Additional 10% Reduction Of Intra-Ocular Pressure
Official Title  ICMJE Determination Of Predictive Factors Allowing To An Additional 10% Reduction Of Intra-Ocular Pressure After A 12-Week Treatment With Latanoprost 0.005% / Timolol 0.5% Fixed Combination (Xalacom) In Previously Treated Patients With Open Angle Glaucoma Or Ocular Hypertension
Brief Summary To determine the predictive factors of a positive response to latanoprost 0.005% / timolol 0.5% fixed combination (defined as a 10% IOP reduction from baseline), after 12 weeks of treatment (age, sex, ethnic origin, patient's medical history, family history of OAG or OHT, concomitant systemic treatment with beta-blockers, etiology, IOP at baseline, corneal thickness, compliance, and adverse events).
Detailed Description Not Provided
Study Type  ICMJE Interventional
Study Phase  ICMJE Phase 3
Study Design  ICMJE Allocation: Non-Randomized
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Condition  ICMJE
  • Glaucoma, Primary Open Angle (POAG)
  • Ocular Hypertension
Intervention  ICMJE
  • Procedure: GSS questionnaire
    D0, D30 and D84
  • Procedure: IOP
    D0, D30 and D84
  • Drug: LATANOPROST 0.005% / TIMOLOL 0.5% FIXED COMBINATION
    in the evening during 84 days
    Other Name: XALACOM
  • Procedure: Visual acuity
    D0 and D84
Study Arms  ICMJE
  • Experimental: Active
    Intervention: Drug: LATANOPROST 0.005% / TIMOLOL 0.5% FIXED COMBINATION
  • Procedure
    Interventions:
    • Procedure: GSS questionnaire
    • Procedure: IOP
    • Procedure: Visual acuity
Publications * Sellem E, Rouland JF, Baudouin C, Bron A, Denis P, Nordmann JP, Renard JP. Predictors of additional intraocular pressure reduction in patients changed to latanoprost/timolol fixed combination. BMC Ophthalmol. 2010 Mar 26;10:10. doi: 10.1186/1471-2415-10-10.

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Recruitment Information
Recruitment Status  ICMJE Completed
Actual Enrollment  ICMJE
 (submitted: February 19, 2008)		396
Original Enrollment  ICMJE
 (submitted: September 29, 2005)		770
Actual Study Completion Date  ICMJE October 2007
Actual Primary Completion Date October 2007   (Final data collection date for primary outcome measure)
Eligibility Criteria  ICMJE

Inclusion Criteria:

  • Male or female patients,
  • Aged > than equal to 18 years,
  • Patient presenting with an OHT or OAG with an IOP ? 21 mmHg,
  • Patient currently treated with ophthalmic beta-blockers monotherapy and requiring a change of the ophthalmic medication due to insufficient response to treatment,

Exclusion Criteria:

  • Patient currently treated by or having received within the last month any ophthalmic hypotensive agent other than a beta-blocker,
  • Patient presenting any contraindication to latanoprost or timolol,
  • Patient with history of asthma, obstructive broncho-pneumopathy, sinusal bradycardia (pulse rate < 60 bpm), auriculo-ventricular block, cardiac insufficiency, Raynaud disease or any other condition that would preclude the patient from taking the prescribed medication,
  • Patient with known intolerance to benzalkonium chloride or any excipient contained in the trial treatment,
Sex/Gender  ICMJE
Sexes Eligible for Study:All
Ages  ICMJE 18 Years and older   (Adult, Older Adult)
Accepts Healthy Volunteers  ICMJE No
Contacts  ICMJE Contact information is only displayed when the study is recruiting subjects
Listed Location Countries  ICMJE France
Removed Location Countries  
 
Administrative Information
NCT Number  ICMJE NCT00230763
Other Study ID Numbers  ICMJE A6641040
Has Data Monitoring Committee No
U.S. FDA-regulated Product Not Provided
IPD Sharing Statement  ICMJE Not Provided
Responsible Party Pfizer ( Pfizer's Upjohn has merged with Mylan to form Viatris Inc. )
Study Sponsor  ICMJE Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
Collaborators  ICMJE Not Provided
Investigators  ICMJE
Study Director:Pfizer CT.gov Call CenterPfizer
PRS Account Pfizer
Verification Date March 2015

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP